Ling Felce

In 2020 I joined NDM to work in Professor Tao Dong's and Professor Julian Knight's groups. My current focus is on characterising T cell responses against different SARS-CoV-2 epitopes through the use of integrated single cell RNA sequencing and TCR repertoire analysis. This can be linked with experimental functional assays, allowing us to fully understand epitope-specific T cell phenotypes across different COVID-19 severities and over the course of SARS-CoV-2 infection.

I previously undertook postdoctoral positions first with Professor Alison Banham (NDCLS/RDM) in understanding the role of transcription factor FOXP1 in immune evasion in diffuse large B cell lymphoma, and subsequently with Dr Gillian Farnie (NDORMS), where I investigated the epigenetic effects of MLLT1, a histone reader, in breast cancer and acute myeloid leukaemia. 

Prior to my postdoctoral work, I graduated from University of Oxford with a degree in Molecular and Cellular Biochemistry (MBiochem), focusing in my master's year on immunology, virology and oncology. I completed my DPhil in Clinical Pharmacology from the Department of Oncology, University of Oxford, working on the design, production and testing of B-cell targeting cancer vaccines based on different viral vectors. My DPhil was funded by a Medical Research Council Studentship.